News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orexigen Therapeutics, Inc. (OREX)'s Contrave: Is This The Weight Loss Drug We've Been Waiting For?



6/10/2014 8:38:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Will the FDA finally approve Contrave, Orexigen’s hot new diet drug, this week? Expectations are high for this new weight loss medication, which could prove an important anti-obesity aid. The ruling is expected as soon as tomorrow. Now temporarily renamed NB32, Contrave was eagerly awaited when it got a startling thumbs-down from the FDA in 2011. The agency demanded additional research into cardiovascular risks.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES